Key points are not available for this paper at this time.
Infliximab and adalimumab originators dominated first-line biologic therapy for moderate-to-severe UC and CD. Understanding real-world treatment patterns can help assess new treatment uptake and suggest opportunities for improving treatment.
Huynh et al. (Sat,) studied this question.